Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.

Castration Resistant ◽

Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4678 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4678-4678 ◽

Cited By ~ 3

Author(s):

S. Nilsson ◽

C. Parker ◽

I. Haugen ◽

A. Lokna ◽

A. Aksnes ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase I ◽

Bone Metastases ◽

Safety Profile ◽

Combined Analysis ◽

Castration Resistant ◽

Radium 223 ◽

Phase I And Ii

7008 POSTER DISCUSSION Twenty-four-month Safety Data From Phase II Studies of Radium-223 Chloride, a First-in-class Alpha-pharmaceutical With a Highly Favorable Safety Profile for Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases

European Journal of Cancer ◽

10.1016/s0959-8049(11)71959-1 ◽

2011 ◽

Vol 47 ◽

pp. S486 ◽

Cited By ~ 1

Author(s):

S. Nilsson ◽

I. Haugen ◽

A. Aksnes ◽

C.G. O'Bryan-Tear ◽

C. Parker

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Safety Profile ◽

Safety Data ◽

Castration Resistant ◽

Radium 223 ◽

Phase Ii Studies ◽

Favorable Safety

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

The Prostate ◽

10.1002/pros.23893 ◽

2019 ◽

Vol 79 (14) ◽

pp. 1683-1691 ◽

Cited By ~ 2

Author(s):

Oliver Sartor ◽

Daniel Heinrich ◽

Neil Mariados ◽

Maria José Méndez Vidal ◽

Daniel Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 1 ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

Open Label Phase

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

European Journal of Cancer ◽

10.1016/j.ejca.2019.04.007 ◽

2019 ◽

Vol 114 ◽

pp. 107-116 ◽

Cited By ~ 15

Author(s):

Michael J. Morris ◽

Yohann Loriot ◽

Christopher J. Sweeney ◽

Karim Fizazi ◽

Charles J. Ryan ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Dose Escalation ◽

Phase 1 ◽

Castration Resistant ◽

Radium-223 (Ra-223) Re-treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC)

Annals of Oncology ◽

10.1093/annonc/mdw334.06 ◽

2016 ◽

Vol 27 ◽

pp. iv30

Author(s):

G. Procopio ◽

S. Severi ◽

E. Verzoni ◽

M. Sansovini ◽

O. Sartor ◽

...

Keyword(s):

Prostate Cancer ◽

Prospective Study ◽

Bone Metastases ◽

Castration Resistant ◽

Radium 223 ◽

Multicenter Prospective Study ◽

International Multicenter

Radium-223 re-treatment in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up from an international, open-label, phase 1/2 study

European Urology Supplements ◽

10.1016/s1569-9056(18)31441-6 ◽

2018 ◽

Vol 17 (2) ◽

pp. e872-e873

Author(s):

D. Heinrich ◽

L. Nordquist ◽

N. Mariados ◽

M.J. Méndez Vidal ◽

D. Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 1 ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

Open Label Phase

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/ajco.13479 ◽

2020 ◽

Author(s):

Tie Zhou ◽

Fangjian Zhou ◽

Jianming Guo ◽

Hongcheng Shi ◽

Xudong Yao ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Asian Patients ◽

Castration Resistant ◽

1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles

Annals of Oncology ◽

10.1093/annonc/mdu336.17 ◽

2014 ◽

Vol 25 ◽

pp. iv263

Author(s):

C. Parker ◽

N. Vogelzang ◽

O. Sartor ◽

D. Bottomley ◽

R.E. Coleman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Castration Resistant ◽

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2017.6 ◽

2017 ◽

Vol 20 (3) ◽

pp. 289-293 ◽

Cited By ~ 30

Author(s):

D Keizman ◽

M O Fosboel ◽

H Reichegger ◽

A Peer ◽

E Rosenbaum ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Castration Resistant ◽

Radium 223 ◽

International Multicenter ◽

Imaging Response

External-Beam Radiation Therapy (Ebrt) Use and Safety with Radium-223 Dichloride (Ra) in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases (Mets) from the Alsympca Trial

Annals of Oncology ◽

10.1093/annonc/mdu336.16 ◽

2014 ◽

Vol 25 ◽

pp. iv263 ◽

Cited By ~ 2

Author(s):

J.M. O'Sullivan ◽

O. Sartor ◽

C. Parker ◽

P. Hoskin ◽

A. Widmark ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Bone Metastases ◽

External Beam Radiation Therapy ◽

External Beam Radiation ◽

External Beam ◽

Beam Radiation ◽

Castration Resistant ◽